Work

Corrigendum to “Inosine: A broad-spectrum anti-inflammatory against SARS-CoV-2 infection-induced acute lung injury via suppressing TBK1 phosphorylation” [J. Pharm. Anal. 13 (2023) 11–23]

Year: 2025

Type: erratum

Abstract: [This corrects the article DOI: 10.1016/j.jpha.2022.10.002.].

Source: Journal of Pharmaceutical Analysis

DOI: 10.1016/j.jpha.2025.101517

Authors: Ningning Wang, Entao Li, Huifang Deng, Lanxin Yue, Lei Zhou, Rina Su, Baokun He, Chengcai Lai, Gaofu Li, Yuwei Gao, Wei Zhou, Yue Gao

Institutions: Tianjin University of Traditional Chinese Medicine, Chinese Academy of Agricultural Sciences, Jilin Agricultural University, Shanghai Jiao Tong University, Shanghai First People's Hospital

Language: English

Topic: COVID-19 Clinical Research Studies

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,950

Funders: Center for Autonomous Systems and Technologies, National Key Research and Development Program of China

Awards: G7391415263, G7796878946

OpenAlex ID: W7116772340

Cites:

Cited by:

Related to: